Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program

E. Anders Kolb, Richard Gorlick, Peter J. Houghton, Christopher L. Morton, Geoffrey Neale, Stephen T. Keir, Hernan Carol, Richard Lock, Doris Phelps, Min H. Kang, C. Patrick Reynolds, John M. Maris, Catherine Billups, Malcolm A. Smith

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: AZD6244 (ARRY-142886) is a potent small molecule inhibitor of MEK1/2 that is in phase 2 clinical development. Procedures: AZD6244 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel (1 nM-10 μM). In vivo AZD6244 was tested at a dose of 100 mg/kg administered orally twice daily 5 days per week for 6 weeks. Subsequently, AZD6244 was evaluated against two juvenile pilocytic astrocytoma (JPA) xenografts using once and twice daily dosing schedules. Phosphorylation of ERK1/2 was used as a surrogate for in vivo inhibition of MEK1/2 was determined by immunoblotting. Results: At the highest concentration used in vitro (10 μM) AZD6244 only inhibited growth by 50% in 5 of the 23 cell lines. Against the in vivo tumor panels, AZD6244 induced significant differences in EFS distribution in 10 of 37 (27%) solid tumor models and 0 of 6 acute lymphoblastic leukemia (ALL) models. There were no objective responses. Pharmacodynamic studies indicated at this dose and schedule AZD6244 completely inhibited ERK1/2 phosphorylation. AZD6244 was evaluated against two JPA xenografts, BT-35 (wild-type BRAF) and BT-40 (mutant [V600E] BRAF). BT-40 xenografts were highly sensitive to AZD6244, whereas BT-35 xenografts progressed on AZD6244 treatment. Conclusions: At the dose and schedule of administration used, AZD6244 as a single agent had limited in vitro and in vivo activity against the PPTP tumor panels despite inhibition of MEK1/2 activity. However, AZD6244 was highly active against BT-40 JPA xenografts that harbor constitutively activated BRAF, causing complete regressions. Pediatr Blood Cancer.

Original languageEnglish (US)
Pages (from-to)668-677
Number of pages10
JournalPediatric Blood and Cancer
Volume55
Issue number4
DOIs
StatePublished - Oct 2010

Fingerprint

Pediatrics
Heterografts
Astrocytoma
Appointments and Schedules
AZD 6244
Neoplasms
Phosphorylation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunoblotting
Cell Line
Growth

Keywords

  • AZD6244
  • Developmental therapeutics
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this

Kolb, E. A., Gorlick, R., Houghton, P. J., Morton, C. L., Neale, G., Keir, S. T., ... Smith, M. A. (2010). Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 55(4), 668-677. https://doi.org/10.1002/pbc.22576

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. / Kolb, E. Anders; Gorlick, Richard; Houghton, Peter J.; Morton, Christopher L.; Neale, Geoffrey; Keir, Stephen T.; Carol, Hernan; Lock, Richard; Phelps, Doris; Kang, Min H.; Reynolds, C. Patrick; Maris, John M.; Billups, Catherine; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 55, No. 4, 10.2010, p. 668-677.

Research output: Contribution to journalArticle

Kolb, EA, Gorlick, R, Houghton, PJ, Morton, CL, Neale, G, Keir, ST, Carol, H, Lock, R, Phelps, D, Kang, MH, Reynolds, CP, Maris, JM, Billups, C & Smith, MA 2010, 'Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 55, no. 4, pp. 668-677. https://doi.org/10.1002/pbc.22576
Kolb, E. Anders ; Gorlick, Richard ; Houghton, Peter J. ; Morton, Christopher L. ; Neale, Geoffrey ; Keir, Stephen T. ; Carol, Hernan ; Lock, Richard ; Phelps, Doris ; Kang, Min H. ; Reynolds, C. Patrick ; Maris, John M. ; Billups, Catherine ; Smith, Malcolm A. / Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2010 ; Vol. 55, No. 4. pp. 668-677.
@article{fb52c5d0c747457aa79092b22a03ae4f,
title = "Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program",
abstract = "Background: AZD6244 (ARRY-142886) is a potent small molecule inhibitor of MEK1/2 that is in phase 2 clinical development. Procedures: AZD6244 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel (1 nM-10 μM). In vivo AZD6244 was tested at a dose of 100 mg/kg administered orally twice daily 5 days per week for 6 weeks. Subsequently, AZD6244 was evaluated against two juvenile pilocytic astrocytoma (JPA) xenografts using once and twice daily dosing schedules. Phosphorylation of ERK1/2 was used as a surrogate for in vivo inhibition of MEK1/2 was determined by immunoblotting. Results: At the highest concentration used in vitro (10 μM) AZD6244 only inhibited growth by 50{\%} in 5 of the 23 cell lines. Against the in vivo tumor panels, AZD6244 induced significant differences in EFS distribution in 10 of 37 (27{\%}) solid tumor models and 0 of 6 acute lymphoblastic leukemia (ALL) models. There were no objective responses. Pharmacodynamic studies indicated at this dose and schedule AZD6244 completely inhibited ERK1/2 phosphorylation. AZD6244 was evaluated against two JPA xenografts, BT-35 (wild-type BRAF) and BT-40 (mutant [V600E] BRAF). BT-40 xenografts were highly sensitive to AZD6244, whereas BT-35 xenografts progressed on AZD6244 treatment. Conclusions: At the dose and schedule of administration used, AZD6244 as a single agent had limited in vitro and in vivo activity against the PPTP tumor panels despite inhibition of MEK1/2 activity. However, AZD6244 was highly active against BT-40 JPA xenografts that harbor constitutively activated BRAF, causing complete regressions. Pediatr Blood Cancer.",
keywords = "AZD6244, Developmental therapeutics, Preclinical testing",
author = "Kolb, {E. Anders} and Richard Gorlick and Houghton, {Peter J.} and Morton, {Christopher L.} and Geoffrey Neale and Keir, {Stephen T.} and Hernan Carol and Richard Lock and Doris Phelps and Kang, {Min H.} and Reynolds, {C. Patrick} and Maris, {John M.} and Catherine Billups and Smith, {Malcolm A.}",
year = "2010",
month = "10",
doi = "10.1002/pbc.22576",
language = "English (US)",
volume = "55",
pages = "668--677",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Houghton, Peter J.

AU - Morton, Christopher L.

AU - Neale, Geoffrey

AU - Keir, Stephen T.

AU - Carol, Hernan

AU - Lock, Richard

AU - Phelps, Doris

AU - Kang, Min H.

AU - Reynolds, C. Patrick

AU - Maris, John M.

AU - Billups, Catherine

AU - Smith, Malcolm A.

PY - 2010/10

Y1 - 2010/10

N2 - Background: AZD6244 (ARRY-142886) is a potent small molecule inhibitor of MEK1/2 that is in phase 2 clinical development. Procedures: AZD6244 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel (1 nM-10 μM). In vivo AZD6244 was tested at a dose of 100 mg/kg administered orally twice daily 5 days per week for 6 weeks. Subsequently, AZD6244 was evaluated against two juvenile pilocytic astrocytoma (JPA) xenografts using once and twice daily dosing schedules. Phosphorylation of ERK1/2 was used as a surrogate for in vivo inhibition of MEK1/2 was determined by immunoblotting. Results: At the highest concentration used in vitro (10 μM) AZD6244 only inhibited growth by 50% in 5 of the 23 cell lines. Against the in vivo tumor panels, AZD6244 induced significant differences in EFS distribution in 10 of 37 (27%) solid tumor models and 0 of 6 acute lymphoblastic leukemia (ALL) models. There were no objective responses. Pharmacodynamic studies indicated at this dose and schedule AZD6244 completely inhibited ERK1/2 phosphorylation. AZD6244 was evaluated against two JPA xenografts, BT-35 (wild-type BRAF) and BT-40 (mutant [V600E] BRAF). BT-40 xenografts were highly sensitive to AZD6244, whereas BT-35 xenografts progressed on AZD6244 treatment. Conclusions: At the dose and schedule of administration used, AZD6244 as a single agent had limited in vitro and in vivo activity against the PPTP tumor panels despite inhibition of MEK1/2 activity. However, AZD6244 was highly active against BT-40 JPA xenografts that harbor constitutively activated BRAF, causing complete regressions. Pediatr Blood Cancer.

AB - Background: AZD6244 (ARRY-142886) is a potent small molecule inhibitor of MEK1/2 that is in phase 2 clinical development. Procedures: AZD6244 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel (1 nM-10 μM). In vivo AZD6244 was tested at a dose of 100 mg/kg administered orally twice daily 5 days per week for 6 weeks. Subsequently, AZD6244 was evaluated against two juvenile pilocytic astrocytoma (JPA) xenografts using once and twice daily dosing schedules. Phosphorylation of ERK1/2 was used as a surrogate for in vivo inhibition of MEK1/2 was determined by immunoblotting. Results: At the highest concentration used in vitro (10 μM) AZD6244 only inhibited growth by 50% in 5 of the 23 cell lines. Against the in vivo tumor panels, AZD6244 induced significant differences in EFS distribution in 10 of 37 (27%) solid tumor models and 0 of 6 acute lymphoblastic leukemia (ALL) models. There were no objective responses. Pharmacodynamic studies indicated at this dose and schedule AZD6244 completely inhibited ERK1/2 phosphorylation. AZD6244 was evaluated against two JPA xenografts, BT-35 (wild-type BRAF) and BT-40 (mutant [V600E] BRAF). BT-40 xenografts were highly sensitive to AZD6244, whereas BT-35 xenografts progressed on AZD6244 treatment. Conclusions: At the dose and schedule of administration used, AZD6244 as a single agent had limited in vitro and in vivo activity against the PPTP tumor panels despite inhibition of MEK1/2 activity. However, AZD6244 was highly active against BT-40 JPA xenografts that harbor constitutively activated BRAF, causing complete regressions. Pediatr Blood Cancer.

KW - AZD6244

KW - Developmental therapeutics

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=77957071661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957071661&partnerID=8YFLogxK

U2 - 10.1002/pbc.22576

DO - 10.1002/pbc.22576

M3 - Article

C2 - 20806365

AN - SCOPUS:77957071661

VL - 55

SP - 668

EP - 677

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -